Uncategorized
Glaukos Corporation Announces Second Quarter 2022 Financial Results
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2022. Key highlights include: Net sales of $72.7 million in Q2 2022. Glaucoma net sales of $56.1 million and Corneal Health net sales of $16.6 million in Q2 2022. Gross margin of approximately 75%